Is Crisugabalin Signaling the Arrival of a Third Generation of α2δ Ligands? AA Montero
用户SpKYSli5BZgc
1个月前
96
10
已完结
1. 系统已在2026-04-23 11:39:12对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
A Alcántara Montero
CNS Drugs, 2026
Springer
Neuropathic pain continues to pose major therapeutic challenges, with current α2δ ligands offering only modest efficacy and limited tolerability for many patients. Crisugabalin (…

